

hypoglycemics. After a detailed clinical evaluation, which included history suggestive of autonomic dysfunction (syncope, bowel, bladder and sexual dysfunctions, orthostatic hypotension, dyspepsia) necessary and relevant investigations were done to monitor target organ damage (cardiac, hepatorenal, ophthalmic evaluation, nerve conduction studies and electromyography). Patients with evidence of target organ damage and hypertension were not selected. Patients requiring insulin were excluded. Evaluation of autonomic functions was restricted to standard tests of salivation, lacrimation, sweat test, pilomotor response, reflex erythema along with changes in blood pressure and RR interval variation (RRIV) with posture, Valsalva, respiration and cold pressor. They are standard reproducible and internationally accepted methods (3). Sympathetic skin response (SSR) was then measured using a variety of stimuli to prevent adaptation (since repeated use of same stimulus produces quick adaptation and erroneous response) on a Neuropack II and IV model of EMG machine supplied by NIHON KOHDEN, Japan. Measurements were done using cursors and markers of the machine, which had a computer, specially programmed to analyse response and results of SSR.

Dysautonomia for our study was defined by positivity of any two tests.

RESULTS

Our observations are summarised in Table I. In all subjects with clinical features of dysautonomia showing impairment of autonomic functions, the SSR was not elicitable and no patient with evident dysautonomia had a positive SSR (Fig. 1). We found that SSR was not recordable in 67% and recordable in only 33% of symptomatic diabetics. In the asymptomatic group also we observed that SSR was not recordable in 42% diabetics while the autonomic functions were normal and comparable to control.

DISCUSSION

We compared autonomic dysfunction in diabetic with and without symptoms of dysautonomia. Our aim was to observe if electrophysiologic documentation was more sensitive than conventional tests. We found that in 7 diabetics (44%), the SSR was not recordable (Fig. 1) while the patient had no symptom and

TABLE I : Comparison of autonomic functions and SSR in diabetic with and without symptoms of dysautonomia.

Parameter	Symptomatic N=15	Asymptomatic N=19	Control N=15
Vertigo	7 (47%)*	-	-
Syncope	4 (26%)*	-	-
Palpitation	6 (40%)*	-	-
Sweating test impaired	5 (33%)*	-	-
Orthostatic hypotension	6 (40%)*	-	-
RRIV with respiration	5 (33%)*	-	-
Valsalva positive	6 (40%)*	-	-
Cold pressor positive	6 (40%)*	-	-
SSR elicitable	5 (33%)*	11 (58%)	15 (100%)
SSR not elicitable	10 (67%)*	8 (42%)	0 (0%)

*P<0.01

autonomic functions were normal. We presume that SSR is a sensitive test and can be beneficial in detecting early autonomic dysfunction since abnormalities of distal sympathetic function occur in history of diabetic autonomic neuropathy (4). This response may be impaired while other bedside tests of autonomic nervous system may be normal as we observed in our study. This may serve an important marker in the prevention of major catastrophies like mortality from stroke, silent myocardial infarction and complications of autonomic insufficiency produced by diseases like polyneuropathies, alcoholism and ageing.

A large number of physiological changes occur in diabetics including decreased baroreceptor sensitivity, altered hemodynamic reflexes and catecholamine sensitivity which may contribute to higher unexplained mortality and increased vulnerability of hypoxic and ischaemic insults seen in diabetics with cardio and cerebrovascular accidents (3,4). The morphological basis of diabetic autonomic neuropathy is possibly due to both axonal loss and segmental demyelination (5) with enlargement and vacuolation of neurones. Autonomic dysfunction is often present in diabetic

NO	AMPLIFIER		ACQUISITION				WAVE	STIMULATOR (ELECTRIC)				
	SENS (V/Div)	HI-F (Hz)	LO-F (Hz)	ANLY (ms)	DLY (Dly)	CNT		RATE (Hz)	DLY (ms)	INT1 (mA)	INT2 (mA)	DUR (ms)
1	1m	20	1	5K	0	1	S	0	0.0	0.0	0.0	0.2
2	1m	20	1	5K	0	1	S	0	0.0	0.0	0.0	0.2
3	1m	20	1	5K	0	1	S	0	28.2	0.0	0.0	0.2
4	1m	20	1	5K	0	1	S	0	28.2	0.0	0.0	0.2

5
6
7
8

NO	MEASUREMENT LATENCY (FROM TRIGGER) (SEC)							INTERVAL (SEC)	AMPLITUDE L1-L2
	L1	L2	L3	L4	L5	L6	L7		
1	1.60	2.46							781μ
2	1.68	2.54							312μ

3
4
5
6
7
8

No	SCV (m/9)	Dist (mm)	Temp (°C)	Area	V-Range (V-Div)
		L1-L2			
1					1.00m
2					1.00m
3					1.00m
4					1.00m

5
6
7
8




Fig. 1 : Normal S.S.R. (Curve 1) and absent S.S.R. (Curve 2, 3 & 4) of a diabetic.

NO	AMPLIFIER		ACQUISITION				STIMULATOR (ELECTRIC)					
	SENS (V/Div)	HI-F (Hz)	LO-F (Hz)	ANLY (ms)	DLY (Diy)	CNT	WAVE	RATE (Hz)	DLY (ms)	INT1 (mA)	INT2 (mA)	DUR (ms)
1	1m	20	1	5K	0	1	S		0	0.0	0.0	0.2
2	1m	20	1	5K	0	1	S		0	23.6	0.0	0.2
3	1m	20	1	5K	0	1	S		0	30.0	0.0	0.2
4	1m	20	1	5K	0	1	S		0	30.0	0.0	0.2
5	1m	20	1	5K	0	1	S		0	30.0	0.0	0.2
6												
7												
8												

NO	MEASUREMENT LATENCY (FROM TRIGGER) (SEC)							INTERVAL (SEC)	AMPLITUDE
	L1	L2	L3	L4	L5	L6	L7		
1	1.38								
2	1.44								
3	1.38								
4	1.32								
5	1.28								
6									
7									
8									

No	SCV (m/9)	Dist (mm)	Temp (°C)	Area	V-Range (V-Div)
1					1.00m
2					1.00m
3					1.00m
4					1.00m
5					
6					
7					
8					




Fig. 2 : Normal well defined S.S.R. (marked L1) with different stimuli in control.

individuals without autonomic symptoms (6). Evaluation of cardiovascular reflex responses to various stimuli is the best diagnostic aid till date (7) but our results show that SSR may be impaired before any cardiovascular reflex heralded autonomic dysfunction. Many studies have, however, indicated a poor life expectancy once clinical disease is apparent (8). Though electrophysiological abnormalities may occur in patients

without obvious neuropathy, the SSR has been well studied but not adequately standardized (9). Besides sensitivity, it is a simple, rapid and inexpensive procedure. It follows the all or none principle i.e. it is elicitable fully (Fig. 2) or is not elicitable (5), hence standardization is easy and erroneous measurements of latency, amplitude and reproducibility can be prevented.

REFERENCES

1. Ewing DJ, Clark BF. Diabetic autonomic neuropathy a clinical viewpoint. In: Diabetic neuropathy (ed) Dyck PJ, Thomas PK, Ashbury AK. Philadelphia, WB Saunders 1987; 66-88.
2. Ewing DJ, Martyn CN, Young RJ, Clark BF. The value of cardiovascular autonomic function tests, 10 years experience in diabetes. *Diabetes Care* 1985; 8: 491-498.
3. Bannister R, Mathies C. Testing autonomic reflexes. In: Autonomic Failure eds. Bannister R. Oxford University Press 1988; 289-307.
4. Low PA, Zimmerman BR, Dyck PH. Comparison of distal sympathetic with vagal function in diabetic neuropathy. *Muscle Nerve* 1986; 9: 592-596.
5. Low PA, Walsh JC, Huang CY, McLeod JG. The sympathetic nervous system in diabetic neuropathy - a clinical and pathological study. *Brain* 1975; 98: 341-356.
6. Pfeifer MA, Cook D, Brodsky J. Quantitative evaluation of cardiac parasympathetic activity in normal and diabetic man. *Diabetes* 1982; 31: 339-345.
7. Ewing DJ, Clark BF. Diabetic autonomic neuropathy, present insights and future prospects. *Diabetes Care* 1986; 9: 648-656.
8. Ewing DJ, Campbell IW, Clark BF. The natural history of diabetic autonomic neuropathy. *Quarterly J of Med* 1980; 49: 95-108.
9. Knezevic WV, Bjado S. Peripheral autonomic surface potential. A quantitative technique for recording sympathetic conduction in man. *J Neurol Sci* 1985; 67: 239-242.